Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in Needham, Massachusetts.
| Revenue (TTM) | $49.59M |
| Gross Profit (TTM) | $42.21M |
| EBITDA | $-169.86M |
| Operating Margin | -240.50% |
| Return on Equity | -786.00% |
| Return on Assets | -59.40% |
| Revenue/Share (TTM) | $0.62 |
| Book Value | $0.74 |
| Price-to-Book | 4.57 |
| Price-to-Sales (TTM) | 7.51 |
| EV/Revenue | 5.59 |
| EV/EBITDA | -0.19 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -78.60% |
| Shares Outstanding | $87.87M |
| Float | $70.44M |
| % Insiders | 0.67% |
| % Institutions | 93.51% |
Volatility is currently contracting